文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.

作者信息

Stauffer Frédéric, Maira Sauveur-Michel, Furet Pascal, García-Echeverría Carlos

机构信息

Novartis Institute for BioMedical Research, Oncology Drug Discovery, Klybeckstrasse 141, Postfach, CH-4002 Basel, Switzerland.

出版信息

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1027-30. doi: 10.1016/j.bmcl.2007.12.018. Epub 2007 Dec 15.

DOI:10.1016/j.bmcl.2007.12.018
PMID:18248814
Abstract

Imidazo[4,5-c]quinoline derivatives have been discovered and developed as potent and effective modulators of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) pathway to lead to clinical development candidates. The SAR data of representative examples of this compound class and their biological profiling in cellular and in vivo settings are presented and discussed.

摘要

相似文献

[1]
Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.

Bioorg Med Chem Lett. 2008-2-1

[2]
Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway.

Bioorg Med Chem Lett. 2008-6-15

[3]
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Cancer Res. 2009-7-15

[4]
Potential antitumor agents. 37. Synthesis and antitumor activity of guanylhydrazones from imidazo[2,1-b]thiazoles and from the new heterocyclic system thiazolo[2',3':2,3]imidazo[4,5-c]quinoline.

J Med Chem. 2005-4-21

[5]
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.

J Urol. 2009-12

[6]
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Cancer Res. 2008-10-1

[7]
Drug discovery approaches targeting the PI3K/Akt pathway in cancer.

Oncogene. 2008-9-18

[8]
Synthesis and anti-cancer activity of 1,4-disubstituted imidazo[4,5-c]quinolines.

Org Biomol Chem. 2016-1-21

[9]
Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.

Bioorg Med Chem Lett. 2010-3-15

[10]
Differential roles of phosphatidylinositol 3-kinase/akt pathway in retinal ganglion cell survival in rats with or without acute ocular hypertension.

Neuroscience. 2008-4-22

引用本文的文献

[1]
molecular modelling, MM/GBSA binding free energy and molecular dynamics simulation study of novel pyrido fused imidazo[4,5-]quinolines as potential anti-tumor agents.

Front Chem. 2022-9-30

[2]
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment.

Front Pharmacol. 2022-5-9

[3]
Chemical and Structural Strategies to Selectively Target mTOR Kinase.

ChemMedChem. 2021-9-16

[4]
Novel 4-Acrylamido-Quinoline Derivatives as Potent PI3K/mTOR Dual Inhibitors: The Design, Synthesis, and and Biological Evaluation.

Front Chem. 2019-4-24

[5]
Tubulin mRNA stability is sensitive to change in microtubule dynamics caused by multiple physiological and toxic cues.

PLoS Biol. 2019-4-9

[6]
New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.

Bioorg Chem. 2018-11-2

[7]
Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin.

Oncotarget. 2017-11-14

[8]
Facile Synthesis and Photophysical Characterization of New Quinoline Dyes.

J Fluoresc. 2017-1

[9]
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.

Oncotarget. 2016-5-31

[10]
Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Transl Lung Cancer Res. 2015-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索